Loading patent…
AssigneeWuhan Ll Science and Technology Development Co., Ltd.
InventorsJun Lou, Yongkai Chen, Wei Peng, Yihan Zhang, Xiaodan Guo, Li Liu, Junhua Liu, Lina Qian, Chaodong Wang
Estimating the term…
Certain compounds are lysophosphatidic acid receptor antagonists have high LPAR1 antagonist activity and selectivity, low toxicity, good metabolic stability, promising pharmaceutical development prospects, and may be used for preventing or treating LPAR1-related diseases or illnesses. The IC50 values of some of the compounds may be as low as 300 nM or below, even 50 nM or below. In addition, CC50 value range of the compounds may be as high as 200 μM or above. Furthermore, the compounds have good metabolic stability in humans, mice and rats.
A compound, a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a polymorph, an ester, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following compounds:
Dependencies are inferred from the claim text.